JP2023524359A5 - - Google Patents
Info
- Publication number
- JP2023524359A5 JP2023524359A5 JP2022554243A JP2022554243A JP2023524359A5 JP 2023524359 A5 JP2023524359 A5 JP 2023524359A5 JP 2022554243 A JP2022554243 A JP 2022554243A JP 2022554243 A JP2022554243 A JP 2022554243A JP 2023524359 A5 JP2023524359 A5 JP 2023524359A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- ctla
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023191381A JP2024016209A (ja) | 2020-05-12 | 2023-11-09 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023554P | 2020-05-12 | 2020-05-12 | |
| US63/023,554 | 2020-05-12 | ||
| PCT/EP2021/062695 WO2021228978A1 (en) | 2020-05-12 | 2021-05-12 | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023191381A Division JP2024016209A (ja) | 2020-05-12 | 2023-11-09 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524359A JP2023524359A (ja) | 2023-06-12 |
| JP2023524359A5 true JP2023524359A5 (enExample) | 2023-06-26 |
| JP7387912B2 JP7387912B2 (ja) | 2023-11-28 |
Family
ID=75977756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554243A Active JP7387912B2 (ja) | 2020-05-12 | 2021-05-12 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
| JP2023191381A Pending JP2024016209A (ja) | 2020-05-12 | 2023-11-09 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023191381A Pending JP2024016209A (ja) | 2020-05-12 | 2023-11-09 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20220363762A1 (enExample) |
| EP (1) | EP4021940A1 (enExample) |
| JP (2) | JP7387912B2 (enExample) |
| KR (1) | KR20230009354A (enExample) |
| CN (1) | CN114729054A (enExample) |
| AU (3) | AU2021269832B2 (enExample) |
| BR (1) | BR112022021893A2 (enExample) |
| CA (1) | CA3158607A1 (enExample) |
| IL (2) | IL297640A (enExample) |
| MX (1) | MX2022006728A (enExample) |
| TW (2) | TW202535468A (enExample) |
| WO (1) | WO2021228978A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260077026A1 (en) * | 2022-09-07 | 2026-03-19 | The University Of Chicago | Methods for treating cancer with hyperactive adar enzymes |
| WO2025211692A1 (ko) * | 2024-04-02 | 2025-10-09 | (주)에트노바테라퓨틱스 | 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트 |
| WO2025256641A1 (zh) * | 2024-06-13 | 2025-12-18 | 江苏恒瑞医药股份有限公司 | 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US20040042972A1 (en) | 2002-04-11 | 2004-03-04 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| WO2003087335A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by spray drying |
| WO2003087327A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| US7923029B2 (en) | 2002-04-11 | 2011-04-12 | Medimmune Llc | Spray freeze dry of compositions for pulmonary administration |
| CN1745170A (zh) | 2002-12-17 | 2006-03-08 | 米迪缪尼疫苗股份有限公司 | 生物活性材料的高压喷雾干燥 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| EP4245376A3 (en) * | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| US20180079814A1 (en) * | 2015-04-01 | 2018-03-22 | Medimmune Limited | Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer |
| HRP20210602T1 (hr) * | 2016-06-20 | 2021-05-14 | F-Star Delta Limited | Vezujuće molekule koje vežu pd-l1 i lag-3 |
| KR20190057303A (ko) * | 2016-09-27 | 2019-05-28 | 온콜로지, 인크. | β2-당단백질 1의 수준에 기초한 바비툭시마브에 의한 암 치료 방법, 및 이를 위한 에세이 |
| US11571459B2 (en) * | 2017-04-03 | 2023-02-07 | Oncxerna Therapeutics, Inc. | Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents |
| JP7055820B2 (ja) * | 2017-05-26 | 2022-04-18 | ブルーイン バイオサイエンシズ，インコーポレイテッド | 化学塞栓療法剤 |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| US20210260051A1 (en) * | 2018-06-14 | 2021-08-26 | Board Of Regents, The University Of Texas System | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer |
| US20210254069A1 (en) * | 2018-06-15 | 2021-08-19 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
-
2021
- 2021-05-12 TW TW114101922A patent/TW202535468A/zh unknown
- 2021-05-12 US US17/765,585 patent/US20220363762A1/en active Pending
- 2021-05-12 EP EP21726376.3A patent/EP4021940A1/en active Pending
- 2021-05-12 BR BR112022021893A patent/BR112022021893A2/pt unknown
- 2021-05-12 KR KR1020227024530A patent/KR20230009354A/ko not_active Ceased
- 2021-05-12 AU AU2021269832A patent/AU2021269832B2/en active Active
- 2021-05-12 IL IL297640A patent/IL297640A/en unknown
- 2021-05-12 MX MX2022006728A patent/MX2022006728A/es unknown
- 2021-05-12 IL IL311936A patent/IL311936A/en unknown
- 2021-05-12 TW TW110117153A patent/TWI870592B/zh active
- 2021-05-12 WO PCT/EP2021/062695 patent/WO2021228978A1/en not_active Ceased
- 2021-05-12 US US17/318,017 patent/US20210355224A1/en active Pending
- 2021-05-12 CA CA3158607A patent/CA3158607A1/en active Pending
- 2021-05-12 CN CN202180006543.2A patent/CN114729054A/zh active Pending
- 2021-05-12 JP JP2022554243A patent/JP7387912B2/ja active Active
-
2023
- 2023-11-09 JP JP2023191381A patent/JP2024016209A/ja active Pending
-
2024
- 2024-03-28 US US18/620,387 patent/US20240239893A1/en active Pending
- 2024-05-03 AU AU2024202963A patent/AU2024202963B2/en active Active
- 2024-11-28 AU AU2024266949A patent/AU2024266949A1/en active Pending